DADUN
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Daratumumab plus lenalidomide and dexamethasone in relapsed/ refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
Aptamers, a new therapeutic opportunity for the treatment of multiple myeloma
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
Response to novel drugs before and after allogeneic stem cell transplantation in patients with relapsed multiple myeloma
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Roadmap to cure multiple myeloma
